Type 1 diabetes remains a compelling target for disease-modifying therapy (DMT) development. The autoimmune pathophysiology is well characterized, a staging framework is established, and regulatory precedent now exists following the approval of teplizumab. While β-cell preservation has been demonstrated for several DMTs in phase 2 trials, few have advanced to registrational studies. This article is intended to reduce that gap through discussion of key considerations to guide drug developers and sponsors in the translation of type 1 diabetes DMTs. In outlining strategies to optimize overall regulatory strategy, clinical trial design, and end point selection, this framework positions DMT development for type 1 diabetes as not only scientifically feasible but also strategically tractable. Together, these considerations offer a road map to accelerate development and approval, with the goal of decreasing the time to benefit for those living with type 1 diabetes.
- Several disease-modifying therapies have reduced the progressive loss of β-cell function in type 1 diabetes, with efficacy observed across a wide array of underlying therapeutic mechanisms of action.
- These successes highlight opportunities to accelerate the development of novel and repurposed type 1 diabetes treatments; however, only one such therapy has received regulatory approval for clinical use and few phase 3 clinical trials have been performed.
- For bringing emerging therapies to people living with type 1 diabetes as quickly and efficiently as possible, overall regulatory strategy and clinical trial design, especially inclusion criteria and end point selection, are essential, and planning must include their careful consideration.
- The considerations discussed herein represent a feasible and promising road map for developers of disease-modifying therapies and establish that type 1 diabetes remains a promising area for continued investment.

Leave a Reply